Neuroinflammation is not only a consequence of, but also a key driver of neurodegeneration. In neuroinflammation, multiple signalling pathways become chronically dysregulated in both astrocytes and microglia, triggering the excessive and continued release of pro-inflammatory cytokines, chemokines, and neurotoxic molecules, which eventually leads to neuronal damage and degeneration. Modulation of these inflammatory pathways is a promising strategy for the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. To support the discovery and preclinical development of novel therapeutics targeting neuroinflammation, we have developed a platform of in vitro and ex vivo assays that harnesses models of increasing physiological relevance and complexity, to suit your stage in the drug development journey. By meticulously tailoring these assays to your requirements and by coupling them with a flexible range of redouts powered by our cutting-edge technologies, we deliver high-quality data and accelerate your progression to the clinic.

‍